Risk factors analyses are urgently required for determining which variables should guide the selection of the best UCB unit for transplantation in adults. This study evaluated prognostic factors of outcome in 92 adults with hematologic malignancy undergoing single-unit UCBT in a single institution. Conditioning consisted of thiotepa, busulfan, cyclophosphamide or fludarabine, and antithymocyte globulin (ATG). Median age and weight were 31 yr and 71 kg. Degree of HLA was 6/6 in 5, 5/6 in 33, and 4/6 in 54 cases. The median number of nucleated and CD34ϩ cells infused was 2.1 ϫ 10E7/kg and 1 ϫ 10E5/kg respectively. The cumulative incidence of myeloid engraftment, grade III-IV acute GVHD, and non-relapse mortality (NRM) at 100 days was 90%, 18%, and 25% respectively. The cumulative incidence of relapse and the probability of disease-free survival (DFS) at 3 years were 21% and 39% (median follow-up, 26 months). Multivariate analyses showed that the absolute number of CD34ϩ cells in the UCB unit was the most important predictor of myeloid and platelet engraftment. The use of rabbit ATG was related to faster platelet engraftment and lower incidence of acute GVHD. The development of grade II-IV acute GVHD was associated with slower platelet engraftment and greater NRM. Older patients had a greater NRM whereas conditioning with thiotepa, fludarabine, intravenous busulfan as a single daily dose, and rabbit ATG and higher numbers of CD3ϩ cells infused were associated with a lower NRM. Relapse risk was lower for patients with chronic myelogenous leukemia and those transplanted in early stage. The only variable independently associated with DFS was the stage of the disease at transplant. The number of nucleated cells and HLA mismatches did not impact any outcome. These results show that the current criteria for selecting the best unit for UCBT in adults need to be modified.
The influence of HLA mismatches on outcomes of cord blood transplants (CBT) is yet to be fully understood. We hypothesized that donor-recipient mismatches in the host-versus-graft (HVG) and graft-versus-host (GVH) direction impact engraftment, nonrelapse mortality (NRM) and survival after CBT, and addressed the question studying CBT performed in our institution. We also analyzed the possible contribution of HVG and GVH mismatches, and graft-versus-graft mismatches in predicting which CB unit would prevail after double CB transplants. We studied 91 patients. Diagnoses were high-risk hematologic malignancies (nϭ85; 93%) or non-malignant disorders (nϭ6; 7%). Conditioning was myeloablative (nϭ86; 95%), while patients not eligible for high-dose therapy received reduced-intensity (nϭ5; 5%) regimens. ATG was part of the preparative regimen in 45 cases (49%). Graft-versushost disease (GVHD) prophylaxis was tacrolimus with (nϭ83; 91%) or without methotrexate (nϭ6; 6%), and cyclosporine and MMF (nϭ2; 2%). Grafts were single (nϭ70; 77%) or double (nϭ21; 23%) CB units. Nine patients received ex-vivo expanded grafts. For patients receiving a double CBT, the engrafted unit was used as the reference for this analysis. HLA-A, B (intermediate resolution) and DRB1 typing (high-resolution) was available for all donor-recipient pairs. Median age was 18 years (range, 1-57); 46 (51%) were younger than 18 years old and 50 patients (55%) were males. The patients were heavily pre-treated with 18 (20%) having received prior autologous transplants. Disease status at CBT was complete remission (CR; nϭ43; 47%) and active disease (nϭ48; 53%). Median number of infused total nucleated cells (TNC) was 3.45x10E7/kg (0.81-23.6). Numbers of mismatches in the HVG direction were as follows: zero (nϭ11), 1 (nϭ37), 2 (nϭ36), 3 (nϭ6), and 4 (nϭ1). Numbers of mismatches in the GVH direction were as follows: zero (nϭ8), 1 (nϭ35), 2 (nϭ41), and 3 (nϭ7). 78 patients engrafted neutrophils (86%) at a median of 22 days (4-60). 65 patients engrafted platelets (71%) at a median of 42 days (0-133). 13 patients (14%) failed to engraft. Grade II-IV and III-IV acute GVHD rates were 49% and 8%, respectively, and chronic GVHD incidence was 33%. 35 patients are alive with a median follow-up of 25 months. 2-year actuarial survival is 21%. 100-day and 1-year NRM is 22% (14-32) and 37% (28-49). Oneyear NRM was 21% (CI: 6-74) for patients that received grafts without HVG HLA mismatches, while it was 33% (CI: 20-54) for those with one mismatch, 47% (CI: 33-67) for those with two mismatches, and 33% (CI: 11-100) for those with three mismatches (PϭNS). The proportion of patients that engrafted was 100% for the group without HVG mismatches, while it was 89%, 85% and 83%, respectively for patients with one, two or three mismatches. The decreasing 2-year survival and worse NRM associated with increasing number of HVG mismatches was limited to the group of patients younger than 18 years. There was no difference in the proportion of patients in CR, or in the distribution of infused TNC/Kg across the HVG mismatch subgroups. There was no correlation between mismatches in the GVH direction and NRM or 2-year survival. In addition, the number and direction of HLA mismatches among CB units and recipient did not predict which unit would prevail after double CB transplants. We conclude that HVG mismatches may influence outcomes of CBT.
UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN CHILDREN WITH ACUTE LEUKEMIA: RISKS AND BENEFITS OF UMBILICAL CORD BLOOD (UCB) VERSUS ALLELE-MATCHED BONE MARROW (BM) Mary Eapen, MD, MS Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI
Though UCB has proven to be an acceptable alternative to BM for transplantation, it is unknown how UCB mismatched at HLA 0-2 loci compares to HLA matched BM. Therefore, we compared transplant results observed in 503 recipients of UCB with those in 116 recipients of allele-matched (at HLA A, B, C, DRB1) BM. Of UCB recipients, 35 were matched at HLA A, B (antigen-level) and DRB1 (allele-level), 201 were mismatched at 1-locus and 267 were mismatched at 2-loci. Compared to recipients of allele matched BM, UCB recipients were younger, non-Caucasian, more likely to have advanced disease at HSCT, less likely to receive radiation and somewhat more likely to receive cyclosporine. As previously observed, probability of neutrophil recovery (Ն500/ul) at day 42 depended on graft type, HLA disparity and cell dose: 97% with BM; 85% with HLA matched UCB; 79% with 1-2 locus mismatched UCB/high cell dose (Ͼ0.3 ϫ 10 8 /kg) and 64% 1-2 locus mismatched UCB/low cell dose (Յ0.3 ϫ 10 8 /kg). Compared to allele-matched BM, risks of grade 2-4 graft-versus-host disease (GVHD) was lower with HLA matched CB (RR 0.45, pϭ0.04) and similar after 1 or 2 loci HLA mismatched UCB. Risks of chronic GVHD were marginally lower after HLA matched or mismatched UCB transplants than after allele-matched BM. Notably, leukemia-free survival (LFS) rates at 5 years were comparable between those receiving allele matched BM (38%) and 1 locus high cell dose (41%), 1 locus low cell dose (37%) or 2 loci (33%) HLA mismatched UCB. The observed higher LFS rate (60%) after HLA matched UCB transplant requires validation in a larger cohort. These results in LFS are in part explained by differences in risks of transplant related mortality (TRM) and relapse between patient populations. Compared to allele-matched BM transplants, TRM was similar in recipients of matched and 1-locus mismatched UCB and higher in recipients of 2-loci mismatched UCB. Conversely, relapse rates were lower in recipients of UCB transplants mismatched at 2-HLA loci. These results are the first to support the use of HLA matched or mismatched UCB grafts with an adequate cell dose as a first line transplant treatment regardless of the availability of a HLA allele-matched BM donor in the setting of acute leukemia in children aged Ͻ16 years. Graft nucleated cell and CD34 ϩ hematopoietic progenitor cell dose are predictors of allogeneic engraftment and survival in umbilical cord blood (UCB) recipients. In this single institution prospective phase II trial, flow cytometric analyses of CD34 ϩ progenitor and lymphocyte populations in unmodified single unit HLAdisparate UCB grafts infused into 31 consecutive adults (median age 41 years, range 20-64) receiving myeloablative conditioning were compared with clinical outcomes. Median infused UCB graft nucleated cells and CD34 ϩ dose was 2.2 ϫ 10 7 /kg and 1.2 ϫ 10 5 /kg respectively. Day to absolute neutrophil count Ͼ 500/L with full donor chimerism averaged 27 days (range 12-41). Univariate analyses demonstrated that UCB graft infused cell doses of CD34 ϩ (pϭ0.015), CD3 ϩ (pϭ0.024) and CD34 ϩ HLADR ϩ CD38 ϩ progenitors (pϭ0.043) correlated with neutrophil engraftment. High-resolution matching for HLA-Class II (DRB1) resulted in improved event-free survival (EFS) (pϭ0.02) and decreased risk for acute graft versus host disease (GVHD) (pϭ0.004). Early mortality (prior to post-transplant day ϩ28) occurred in three patients, while twenty-six patients achieved myeloid engraftment. These results suggest that UCB graft matching at DRB1 is an important risk factor for acute GVHD and survival, while higher UCB graft cell doses of CD34 ϩ , committed CD34 ϩ progenitors and CD3 ϩ T-cells favorably influence UCB allogeneic engraftment. John E. Wagner, M.D. and Claudio Brunstein, M.D. Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455 Cryopreserved umbilical cord blood (UCB) has been investigated as a potential strategy for augmenting the pool of acceptable donors, reducing the risks of acute and chronic graft-versus-host disease (GVHD) and improving survival. Cell dose, however, has clearly been identified as a major limitation, often preventing the consideration of UCB for adult recipients. Recipients of Ͻ2.5 ϫ 10 7 nucleated cells/kg have slow hematopoietic recovery and sig-nificantly lower incidence of engraftment. Therefore, we explored the potential of infusing two partially HLA matched units to augment cell dose in patients who did not have an UCB graft containing Ͻ2.5 ϫ 10 7 nucleated cells/kg. The underlying hypothesis is that the addition of the second unit will enhance engraftment and speed of hematopoietic recovery. One-hundred and twentytwo patients [median age 23.2 years (range: 2.9-45.8); median weight 64 kg (range: 12.6-148.6)] with high-risk hematologic malignancy were transplanted with a partially HLA-matched UCB graft (70% received two units) after a single myeloablative conditioning consisting of fludarabine 75 mg/m2, cyclophosphamide 60 mg/kg and total body irradiation 1320 cGy. All received cyclosporine and mycophenolate mofetil posttransplant immunoprophylaxis. Patients had AML (nϭ51), ALL (nϭ46), CML (nϭ10), MDS (nϭ4) or NHL (nϭ11). The median total infused dose was 4.4 ϫ 10 7 NC/kg (range 1.1-13.9). The incidence of neutrophil recovery was 91% (95% CI, 86-96) at a median of 23 days with no difference observed in recipients of one or two units. Only CD34 cell dose predicted incidence and speed of recovery. After engraftment, one unit predominated in Ͼ90% with no factor (nucleated cell dose, CD34ϩ cell dose, HLA-match, ABO, sex, or order of infusion) predicting which unit would predominate long term. Incidence of grades II-IV and III-IV acute graft-versus-host disease (GVHD) was 55% (95% CI, 44-66) and 17% (95% CI, 9-25) at day 100 with an increased incidence of grade II disease only in recipients of two units. Incidences of transplant-related mortality and relapse was 25% (95% CI, 17-33) at 1 year and 22% (95% CI, 12-32) at 2 years, respectively. Probabilities of overall and event-free survival are 59% (95% CI, 49-69) and 51% (95% CI, 40-62) at 2 years, respectively. Notably, recipients of two units had a trend toward reduced relapse and improved event-free survival. These data suggest that 1) double unit UCBT is safe with one unit predominating over time, 2) double unit UCBT may extend the application of UCB to nearly all adults and adolescents, and 3) double UCBT may be associated with lower relapse and higher survival in those with acute leukemia in complete remission. A NIH-CTN sponsored, multi-institutional randomized trial comparing outcomes in recipients of single versus double UCB transplantation is open for accrual.
INFLUENCE OF HLA DISPARITY AND GRAFT LYMPHOCYTES ON ALLO-GENEIC ENGRAFTMENT AND SURVIVAL AFTER UMBILICAL CORD BLOOD TRANSPLANT IN ADULTS

DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATION AFTER MY-ELOABLATION
EFFECT OF CD2ON CORD BLOOD, AND OTHER MEANS TO ENHANCE ENGRAFTMENT OF HEMATOPOIETIC STEM CELLS Hal E. Broxmeyer, Ph.D. Indiana University School of Medicine, Indianapolis, Indiana
A major goal of our laboratory and the focus of this presentation is to enhance the efficiency of cord blood transplantation through a better understanding of the mechanisms regulating hematopoiesis, and hematopoietic stem (HSC) and progenitor cell functions. We have found that inhibition of CD26/Dipeptidylpeptidase IV (DPPIV) with small peptides, such as Diprotin A (Ile-Pro-Ile) or Val-Pyr enhance the capacity of human cord blood CD34 ϩ cells and mouse Sca1 ϩ c-kit ϩ Lin Ϫ bone marrow cells to respond to the chemotactic activity of stromal cell derived factor (SDF-1/ CXCL12) in vitro (Christopherson, et al. J. Immunol 169:7000-7008, 2002) and they enhance donor mouse bone marrow HSC homing and engraftment of lethally irradiated recipient mice in both a competitive and a non-competitive assay (Christopherson, et al. Science 30:1000 -1003 , 2004 . Enhanced engrafting capability of gene transduced mouse bone marrow cells into lethally irradiated mice (Tian, et al. Gene Therapy 13:652-658, 2006) and mouse bone marrow cells in utero into mice (Peranteau, et al. Blood 108:4268-4274, 2006) has been noted by others in the context of Diprotin A inhibition of CD26/DPPIV on donor cells. We now report that inhibition of CD26/DPPIV in human cord blood CD34 ϩ cells enhances their engraftment of non obese diabetic (NOD)/Severe Combined Immunodeficient (SCID) mice (Campbell, et al. Stem Cells and Development [SCD], 16:347-353, 2007) . Others have seen Diprotin A enhancement of CD34 ϩ cord blood (Christopherson, et al. SCD 16:355-360, 2007) and G-CSF mobilized adult peripheral blood CD34 ϩ (Kawai, et al. SCD 16:361-370, 2007) cells respectively by pretreating donor CD34 ϩ cells, or
